Meeting
2022 ASCO Annual Meeting
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Presenter
Elena Garralda, MD, MSc
Vall d'Hebron Institute of Oncology (VHIO)
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04234113
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2502)
DOI
10.1200/JCO.2022.40.16_suppl.2502
Abstract #
2502
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.
Speaker: Anthony W. Tolcher, MD, FASCO
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
Speaker: Jing Huang, MD
Videos & Slides
2022 ASCO Annual Meeting
Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.
Speaker: Aung Naing, MD, FACP